Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769288 · ClinicalTrials.gov registry record · Phase 1
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 study of Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00769288: Completed Phase 1 study of Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma, sponsored by National Cancer Institute (NCI).
NCT00769288 is a Phase 1 study of Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants, below the 60-participant average among 25 other Anaplastic Large Cell Lymphoma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00769288, a Phase 1 study of Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Drugs used in chemotherapy, such as FAU, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. This phase I trial is studying the side effects and best dose of FAU in treating patients with advanced solid tumors or lymphoma.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- OTHER pharmacogenomic studies
- DRUG 2'-F-ara-deoxyuridine
- OTHER positron emission tomography
Study Locations (1)
Michigan
- Wayne State University - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-07 |
| Phase | Phase 1 |
What the finished NCT00769288 record still lists
NCT00769288 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 25 other Anaplastic Large Cell Lymphoma trials with a reported enrollment target (80% lower).
The record links to 10 conditions, with Anaplastic Large Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00769288 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT00769288 about?
NCT00769288 is a clinical study titled "FAU in Treating Patients With Advanced Solid Tumors or Lymphoma". Drugs used in chemotherapy, such as FAU, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. This phase I trial is studying the side effects and best dose of FAU in treating patients with advanced solid tumors or lymphoma.
What is the current status of trial NCT00769288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-07.
What conditions does trial NCT00769288 study?
This clinical trial studies the following conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma.
What interventions are being tested in trial NCT00769288?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), pharmacogenomic studies (OTHER), 2'-F-ara-deoxyuridine (DRUG), positron emission tomography (OTHER).
Who is sponsoring clinical trial NCT00769288?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00769288 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Large Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00769288's enrollment target sits among peer trials
12 24th of 25 higher than 2 of 25 other Anaplastic Large Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anaplastic Large Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
RECRUITING · Phase 1
-
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
ACTIVE NOT RECRUITING · Phase 1
-
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia